Michael Wolff, MD

Burlington, North Carolina

0 studies enrolling now · 1 studies all time

What they study most

Bladder Cancer, Carcinoma in Situ

Studies at this site

• Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) — Completed